Drug target to combat three coronavirus diseases identified by researchers
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
List view / Grid view
Researchers studying the PLpro binding site of three coronaviruses, including SARS-CoV-2, say the BL2 loop could be targeted by antiviral drugs.
In human cells, a drug candidate called PF-00835231 has demonstrated success at blocking the reproduction of SARS-CoV-2.
As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
A new tool called COVID-3D that monitors SARS-CoV-2 genome mutations could aid drug and vaccine development, its creators say.
Using scanning electron microscopy, researchers have captured images of epithelial cell cultures infected by SARS-CoV-2.
Researchers suggest possible therapies for macrophage activation syndrome (MAS), a feature of cytokine storm and a major cause of death in severe COVID-19 patients.
Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
Researchers reveal that activating the MHC class II transactivator (CIITA) and CD74 genes protected cells against infection by Ebola and SARS-CoV-2.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
Researchers report that while the spike protein and RNA polymerase proteins have stabilised, other regions of the SARS-CoV-2 genome are becoming increasingly variable.
Scientists have revealed that the cytokines IL-6 and TNF-α are two biomarkers of inflammation that can predict the severity of COVID-19.
Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.